Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Neurology

Demyelinating Disorders

Modulation of retinal atrophy with rituximab in multiple sclerosis

Neurology® | May 28, 2021 Demyelinating Disorders

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis

Journal of Neurology, Neurosurgery & Psychiatry | May 18, 2021 Demyelinating Disorders

Association of a marker of N-acetylglucosamine with progressive multiple sclerosis and neurodegeneration

JAMA | May 14, 2021 Demyelinating Disorders

Long-term effectiveness of fingolimod for multiple sclerosis in a real-world clinical setting

European Neurology | Apr 11, 2021 Demyelinating Disorders

Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial

JAMA | Apr 07, 2021 Demyelinating Disorders

Microstructural changes in the left mesocorticolimbic pathway are associated with the comorbid development of fatigue and depression in multiple sclerosis

Journal of Neuroimaging | Feb 04, 2021 Demyelinating Disorders

Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study

Neurology® | Jan 29, 2021 Demyelinating Disorders

Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis

Journal of Neuroimmunology | Dec 23, 2020 Demyelinating Disorders

Course of neuropsychological impairment during natalizumab associated progressive multifocal leukoencephalopathy

European Journal of Neurology | Oct 27, 2020 Demyelinating Disorders

Natalizumab vs fingolimod for patients with active relapsing-remitting multiple sclerosis: Results from REVEAL, a prospective, randomised head-to-head study

BMJ Open | Oct 23, 2020 Demyelinating Disorders

« Prev 1 2 3 4 5 … 32 Next »

Modulation of retinal atrophy with rituximab in multiple sclerosis

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis

Association of a marker of N-acetylglucosamine with progressive multiple sclerosis and neurodegeneration

Long-term effectiveness of fingolimod for multiple sclerosis in a real-world clinical setting

Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial

Microstructural changes in the left mesocorticolimbic pathway are associated with the comorbid development of fatigue and depression in multiple sclerosis

Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study

Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis

Course of neuropsychological impairment during natalizumab associated progressive multifocal leukoencephalopathy

Natalizumab vs fingolimod for patients with active relapsing-remitting multiple sclerosis: Results from REVEAL, a prospective, randomised head-to-head study

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Top Foods to Combat Winter Illness

Pulmonary Embolism: MCQs Challenge

The Role of Nutrition in Enhancing Fertility for Men and Women

Modulation of retinal atrophy with rituximab in multiple sclerosis

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis

Association of a marker of N-acetylglucosamine with progressive multiple sclerosis and neurodegeneration

Long-term effectiveness of fingolimod for multiple sclerosis in a real-world clinical setting

Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial

Microstructural changes in the left mesocorticolimbic pathway are associated with the comorbid development of fatigue and depression in multiple sclerosis

Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study

Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis

Course of neuropsychological impairment during natalizumab associated progressive multifocal leukoencephalopathy

Natalizumab vs fingolimod for patients with active relapsing-remitting multiple sclerosis: Results from REVEAL, a prospective, randomised head-to-head study

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Top Foods to Combat Winter Illness

Pulmonary Embolism: MCQs Challenge

The Role of Nutrition in Enhancing Fertility for Men and Women

Select Specialty

Select Topic